Orphan Drug Maker Chiasma Raises $101.8M in IPO
Orphan disease drug developer Chiasma raised $ one zero one.8 million in its initial public providing, $ 20 million more than the higher end of the Newton, MA-based totally biopharma company’s previous projection.
Chiasma (NASDAQ: CHMA) is the use of many of the cash to construct out its U.S. gross sales and advertising operations as it readies itself for the potential launch of its lead remedy that ambitions acromegaly. The situation, which can result in loss of life, is brought about when the pituitary gland releases excess human boom hormone, therefore elevating the body’s insulin levels.
It will increase the scale of bones within the limbs and face. Andre Roussimoff, higher often called Andre the enormous, suffered from it. The situation is most often handled with injectables, and Chiasma is in the hunt for to gain regulatory approval of an oral remedy.
Chiasma has accomplished a phase 3 trial for a drug, oral octreotide, which is a pure inhibitor of human boom hormone. It submitted a new drug software on June 15 to the FDA, and already has orphan drug designation.
it is considered one of more than one companies developing therapeutics according to peptides that may be swallowed like tablets instead of injected into the bloodstream. Peptides can have certain capabilities chemical medicine lack and may attain objectives that protein-based totally drugs can’t—but they’re fragile and spoil down easily in the body, as Xconomy’s national Biotech Editor Alex Lash wrote in a narrative about Protagonist Therapeutics.
Protagonist, which announced a $ forty million project round these days, is testing its drug in inflammatory bowel illness. Celgene (NASDAQ: CELG) is paying $ 7.2 billion deal to buy San Diego’s Receptos (NASDAQ: RCPT), which is studying its lead drug candidate in late-stage trials for ulcerative colitis and more than one sclerosis. Ulcerative colitis is an inflammatory bowel illness that can damage the colon.
Chiasma also plans to use some of the proceeds on pursuing a phase three trial in Europe for the remedy, as well as starting a phase 2 trial for it in treating neuroendocrine tumors, Chiasma mentioned in regulatory filings. the company also plans to select a second product candidate in 2016, and initiate pre-scientific development of a third the following yr, it said in a filing.
in the IPO, Chiasma offered 6.4 million shares at $ sixteen per share. It had hoped to sell 5.4 million shares for $ 13 to $ 15 each and every.
The stock opened at $ 20.50, and rose to $ 21.sixty one as of eleven:40 a.m. in new york.
(109)
